Home
IMNM
IMNM News

Latest Immunome Inc. (IMNM) News on September 14, 2025

MT Newswires

9 days ago

Craig-Hallum Initiates Immunome at Buy With $26 Price Target

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

9 days ago

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome (IMNM) Upgraded to Buy: Here's What You Should Know

Zacks

3 months ago

Immunome (IMNM) Upgraded to Buy: Here's What You Should Know

Wall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High?

Zacks

3 months ago

Wall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High?

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

3 months ago

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a Bet

Zacks

4 months ago

Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a Bet

Immunome to Present at Upcoming Investor Conferences

Business Wire

4 months ago

Immunome to Present at Upcoming Investor Conferences

Immunome First Quarter 2025 Earnings: Beats Expectations

Simply Wall St.

4 months ago

Immunome First Quarter 2025 Earnings: Beats Expectations

All You Need to Know About Immunome (IMNM) Rating Upgrade to Buy

Zacks

4 months ago

All You Need to Know About Immunome (IMNM) Rating Upgrade to Buy

Immunome, Inc. (IMNM) Reports Q1 Loss, Tops Revenue Estimates

Zacks

4 months ago

Immunome, Inc. (IMNM) Reports Q1 Loss, Tops Revenue Estimates

Immunome Reports First Quarter 2025 Financial Results and Provides Business Update

Business Wire

4 months ago

Immunome Reports First Quarter 2025 Financial Results and Provides Business Update

Wall Street Analysts Believe Immunome (IMNM) Could Rally 249.93%: Here's is How to Trade

Zacks

4 months ago

Wall Street Analysts Believe Immunome (IMNM) Could Rally 249.93%: Here's is How to Trade

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

4 months ago

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Alnylam (ALNY) Moves 8.5% Higher: Will This Strength Last?

Zacks

5 months ago

Alnylam (ALNY) Moves 8.5% Higher: Will This Strength Last?

Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference

Business Wire

5 months ago

Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

5 months ago

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Clay Siegall Bought 20% More Shares In Immunome

Simply Wall St.

5 months ago

Clay Siegall Bought 20% More Shares In Immunome

Argus Research

6 months ago

Daily – Vickers Top Buyers & Sellers for 03/27/2025

Closing Bell Movers: GameStop gains 7% on earnings, bitcoin announcement

TipRanks

6 months ago

Closing Bell Movers: GameStop gains 7% on earnings, bitcoin announcement

MT Newswires

6 months ago

Immunome Insider Bought Shares Worth $999,459, According to a Recent SEC Filing

Argus Research

6 months ago

Daily – Vickers Top Buyers & Sellers for 03/26/2025

Immunome Full Year 2024 Earnings: Misses Expectations

Simply Wall St.

6 months ago

Immunome Full Year 2024 Earnings: Misses Expectations

Immunome, Inc. (IMNM) Reports Q4 Loss, Misses Revenue Estimates

Zacks

6 months ago

Immunome, Inc. (IMNM) Reports Q4 Loss, Misses Revenue Estimates

MT Newswires

6 months ago

Immunome 2024 Net Loss Narrows

Immunome Reports Full Year 2024 Financial Results and Provides Business Update

Business Wire

6 months ago

Immunome Reports Full Year 2024 Financial Results and Provides Business Update

With 59% ownership of the shares, Immunome, Inc. (NASDAQ:IMNM) is heavily dominated by institutional owners

Simply Wall St.

6 months ago

With 59% ownership of the shares, Immunome, Inc. (NASDAQ:IMNM) is heavily dominated by institutional owners

Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC

Business Wire

6 months ago

Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

6 months ago

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome to Present at Upcoming March Conferences

Business Wire

7 months ago

Immunome to Present at Upcoming March Conferences

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

7 months ago

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Insider Stock Buying Reaches US$2.82m On Immunome

Simply Wall St.

7 months ago

Insider Stock Buying Reaches US$2.82m On Immunome

MT Newswires

7 months ago

Immunome Closes Public Offering of Shares

Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Business Wire

7 months ago

Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

MT Newswires

7 months ago

Immunome Prices $150 Million Stock Offering

Immunome Announces Pricing of Upsized Public Offering of Common Stock

Business Wire

7 months ago

Immunome Announces Pricing of Upsized Public Offering of Common Stock

Immunome Announces Proposed Public Offering of Common Stock

Business Wire

7 months ago

Immunome Announces Proposed Public Offering of Common Stock

Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Business Wire

8 months ago

Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

MT Newswires

8 months ago

Immunome Obtains Worldwide License to Hummingbird's Monoclonal Antibodies

Hummingbird Bioscience Licenses Novel Antibodies to Immunome

GlobeNewswire

8 months ago

Hummingbird Bioscience Licenses Novel Antibodies to Immunome

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

8 months ago

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

9 months ago

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference

Business Wire

10 months ago

Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference

Argus Research

10 months ago

Daily – Vickers Top Buyers & Sellers for 11/26/2024

MT Newswires

10 months ago

Immunome Insider Bought Shares Worth $962,181, According to a Recent SEC Filing

MT Newswires

10 months ago

Immunome Files Prospectus for Stock Offering By Selling Shareholders

Immunome Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

10 months ago

Immunome Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Immunome, Inc. (IMNM) Reports Q3 Loss, Misses Revenue Estimates

Zacks

10 months ago

Immunome, Inc. (IMNM) Reports Q3 Loss, Misses Revenue Estimates

Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update

Business Wire

10 months ago

Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update

ImmunityBio (IBRX) Reports Q3 Loss, Tops Revenue Estimates

Zacks

10 months ago

ImmunityBio (IBRX) Reports Q3 Loss, Tops Revenue Estimates

MT Newswires

10 months ago

Stephens Starts Immunome With Overweight Rating, $30 Price Target

Immunome to Present at Guggenheim’s Inaugural Healthcare Innovation Conference

Business Wire

10 months ago

Immunome to Present at Guggenheim’s Inaugural Healthcare Innovation Conference

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

10 months ago

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome Advances with Strategic Asset Acquisition and Agreement

TipRanks

10 months ago

Immunome Advances with Strategic Asset Acquisition and Agreement

Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021

Business Wire

a year ago

Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021

Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium

Business Wire

a year ago

Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium

Immunome Appoints Roee Shahar as Executive Vice President, Commercial

Business Wire

a year ago

Immunome Appoints Roee Shahar as Executive Vice President, Commercial

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

a year ago

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Business Wire

a year ago

Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Business Wire

a year ago

Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Immunome Stock Sees RS Rating Jump To 91

Investor's Business Daily

a year ago

Immunome Stock Sees RS Rating Jump To 91

Immunome Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

a year ago

Immunome Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Immunome, Inc. (IMNM) Reports Q2 Loss, Misses Revenue Estimates

Zacks

a year ago

Immunome, Inc. (IMNM) Reports Q2 Loss, Misses Revenue Estimates

MT Newswires

a year ago

Immunome Q2 Net Loss Widens, Revenue Drops

Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update

Business Wire

a year ago

Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update

Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities

Business Wire

a year ago

Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities

Immunome Insiders Added US$2.67m Of Stock To Their Holdings

Simply Wall St.

a year ago

Immunome Insiders Added US$2.67m Of Stock To Their Holdings

Immunome Appoints Phil Tsai as Chief Technical Officer

Business Wire

a year ago

Immunome Appoints Phil Tsai as Chief Technical Officer

Argus Research

a year ago

Daily – Vickers Top Buyers & Sellers for 05/22/2024

Insider Buying: Immunome Inc's CEO Acquires 100,000 Shares

GuruFocus.com

a year ago

Insider Buying: Immunome Inc's CEO Acquires 100,000 Shares

MT Newswires

a year ago

Immunome Insider Bought Shares Worth $1,388,072, According to a Recent SEC Filing

MT Newswires

a year ago

Immunome Completes Purchase of Antibodies From Atreca

Immunome Announces Completion of Purchase of Assets from Atreca

Business Wire

a year ago

Immunome Announces Completion of Purchase of Assets from Atreca

MT Newswires

a year ago

Immunome Appoints Max Rosett as CFO

Immunome Announces Promotion of Max Rosett to Chief Financial Officer

Business Wire

a year ago

Immunome Announces Promotion of Max Rosett to Chief Financial Officer

Immunome, Inc. (IMNM) Reports Q1 Loss, Misses Revenue Estimates

Zacks

a year ago

Immunome, Inc. (IMNM) Reports Q1 Loss, Misses Revenue Estimates

Immunome Reports First Quarter 2024 Financial Results and Provides Business Update

Business Wire

a year ago

Immunome Reports First Quarter 2024 Financial Results and Provides Business Update

Immunome to Present at 2024 Bank of America Healthcare Conference

Business Wire

a year ago

Immunome to Present at 2024 Bank of America Healthcare Conference

Immunome Appoints Kinney Horn as Chief Business Officer

Business Wire

a year ago

Immunome Appoints Kinney Horn as Chief Business Officer

MT Newswires

a year ago

--JPMorgan Starts Immunome With Overweight Rating, $24 Price Target

Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for

Zacks

a year ago

Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for

Immunome Appoints Sandra M. Swain to Board of Directors

Business Wire

a year ago

Immunome Appoints Sandra M. Swain to Board of Directors

Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting

Business Wire

a year ago

Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting

New Strong Sell Stocks for April 4th

Zacks

a year ago

New Strong Sell Stocks for April 4th

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

Business Wire

a year ago

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala

Business Wire

a year ago

Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala

Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome

GlobeNewswire

a year ago

Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome

Immunome, Inc. (NASDAQ:IMNM) surges 7.6%; individual investors who own 42% shares profited along with institutions

Simply Wall St.

a year ago

Immunome, Inc. (NASDAQ:IMNM) surges 7.6%; individual investors who own 42% shares profited along with institutions

Business Wire

2 years ago

Immunome to Participate in the Leerink Partners Global Biopharma Conference

Business Wire

2 years ago

Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference

Business Wire

2 years ago

Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

GlobeNewswire

2 years ago

Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

Business Wire

2 years ago

Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Business Wire

2 years ago

Immunome Announces Pricing of Public Offering of Common Stock

Business Wire

2 years ago

Immunome Announces Proposed Public Offering of Common Stock

Insiders See US$1.25m Investment In Immunome Jump Last Week

Simply Wall St.

2 years ago

Insiders See US$1.25m Investment In Immunome Jump Last Week

Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up

Zacks

2 years ago

Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up

Business Wire

2 years ago

Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals

Business Wire

2 years ago

Immunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

WEBINAR INVITATION | Okeanis Eco Tankers, Corp. (NYSE: ECO) (OSLO: OET) Live Investor Webinar on Friday, February 2, 2024 at 9:00 am ET

GlobeNewswire

2 years ago

WEBINAR INVITATION | Okeanis Eco Tankers, Corp. (NYSE: ECO) (OSLO: OET) Live Investor Webinar on Friday, February 2, 2024 at 9:00 am ET

SpartanNash Recognized by Newsweek as One of America's Greatest Workplaces for Diversity 2024

PR Newswire

2 years ago

SpartanNash Recognized by Newsweek as One of America's Greatest Workplaces for Diversity 2024

Share on Social Networks: